Dynavax Technologies Corporation raised revenue guidance for the full year 2023. For the year, the company expected HEPLISAV-B net product revenue to be in the range of $200 million to $215 million compared to the prior range of $165 million to $185 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.11 USD | -1.51% | +3.54% | -20.53% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.53% | 1.45B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- DVAX Stock
- News Dynavax Technologies Corporation
- Dynavax Technologies Corporation Raises Revenue Guidance for the Full Year 2023